Sunitinib in Treating Young Patients With Refractory Solid Tumors

NCT00387920 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Central Nervous System Metastases
Childhood Central Nervous System Choriocarcinoma
Childhood Central Nervous System Embryonal Tumor
Childhood Central Nervous System Germ Cell Tumor
Childhood Central Nervous System Germinoma
Childhood Central Nervous System Mixed Germ Cell Tumor
Childhood Central Nervous System Teratoma
Childhood Central Nervous System Yolk Sac Tumor
Recurrent Childhood Central Nervous System Embryonal Tumor
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG: sunitinib malate
OTHER: pharmacological study
PROCEDURE: dynamic contrast-enhanced magnetic resonance imaging
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)